Kyntra Bio, Inc. (KYNB) stock
KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.95−0.09 (-4.41%)
Close on Nov 18, 2026Market cap $7.90MP/E 0.0Yield –
Kyntra Bio revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Kyntra Bio's revenue for the twelve months ending Jun 30, 2026 was $4.62M, down 37.1% year over year. For fiscal 2025 it was $6.44M, down 78.3% from the year before. Over ten years it grew -28.4% a year on average. The highest annual figure on record is $256.58M in fiscal 2019.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.44M | -78.3% |
| FY2024 | Dec 31, 2024 | $29.62M | -36.7% |
| FY2023 | Dec 31, 2023 | $46.80M | -66.7% |
| FY2022 | Dec 31, 2022 | $140.73M | -40.2% |
| FY2021 | Dec 31, 2021 | $235.31M | +33.5% |
| FY2020 | Dec 31, 2020 | $176.32M | -31.3% |
| FY2019 | Dec 31, 2019 | $256.58M | +20.5% |
| FY2018 | Dec 31, 2018 | $212.96M | +62.6% |
| FY2017 | Dec 31, 2017 | $131.00M | -28.5% |
| FY2016 | Dec 31, 2016 | $183.19M | +1.3% |
| FY2015 | Dec 31, 2015 | $180.83M | +31.4% |
| FY2014 | Dec 31, 2014 | $137.60M | +34.7% |
| FY2013 | Dec 31, 2013 | $102.17M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.47M | -209.3% |
| Q1 FY2026 | Mar 31, 2026 | $3.74M | +36.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.28M | -59.3% |
| Q3 FY2025 | Sep 30, 2025 | $1.08M | +774.8% |
| Q2 FY2025 | Jun 30, 2025 | $1.35M | +35.1% |
| Q1 FY2025 | Mar 31, 2025 | $2.74M | -89.2% |
| Q4 FY2024 | Dec 31, 2024 | $3.14M | -88.4% |
| Q3 FY2024 | Sep 30, 2024 | $123.00K | -99.7% |
| Q2 FY2024 | Jun 30, 2024 | $998.00K | -97.7% |
| Q1 FY2024 | Mar 31, 2024 | $25.36M | -29.9% |
| Q4 FY2023 | Dec 31, 2023 | $27.14M | -21.0% |
| Q3 FY2023 | Sep 30, 2023 | $40.13M | +155.1% |
| Q2 FY2023 | Jun 30, 2023 | $44.32M | +48.7% |
| Q1 FY2023 | Mar 31, 2023 | $36.16M | -40.6% |
| Q4 FY2022 | Dec 31, 2022 | $34.37M | +107.7% |
| Q3 FY2022 | Sep 30, 2022 | $15.74M | -89.9% |
| Q2 FY2022 | Jun 30, 2022 | $29.81M | +22.3% |
| Q1 FY2022 | Mar 31, 2022 | $60.83M | +58.3% |
| Q4 FY2021 | Dec 31, 2021 | $16.54M | -74.5% |
| Q3 FY2021 | Sep 30, 2021 | $155.97M | +254.2% |
| Q2 FY2021 | Jun 30, 2021 | $24.36M | -43.2% |
| Q1 FY2021 | Mar 31, 2021 | $38.43M | +57.5% |
| Q4 FY2020 | Dec 31, 2020 | $65.00M | +715.1% |
| Q3 FY2020 | Sep 30, 2020 | $44.03M | +32.7% |
| Q2 FY2020 | Jun 30, 2020 | $42.89M | -77.6% |
| Q1 FY2020 | Mar 31, 2020 | $24.40M | +2.3% |
| Q4 FY2019 | Dec 31, 2019 | $7.97M | -92.6% |
| Q3 FY2019 | Sep 30, 2019 | $33.17M | +14.3% |
| Q2 FY2019 | Jun 30, 2019 | $191.57M | +335.9% |
| Q1 FY2019 | Mar 31, 2019 | $23.86M | -25.3% |
| Q4 FY2018 | Dec 31, 2018 | $108.06M | +251.6% |
| Q3 FY2018 | Sep 30, 2018 | $29.03M | -28.4% |
| Q2 FY2018 | Jun 30, 2018 | $43.95M | +45.2% |
| Q1 FY2018 | Mar 31, 2018 | $31.93M | +8.4% |
| Q4 FY2017 | Dec 31, 2017 | $30.74M | -13.5% |
| Q3 FY2017 | Sep 30, 2017 | $40.55M | +34.7% |
| Q2 FY2017 | Jun 30, 2017 | $30.27M | – |
| Q1 FY2017 | Mar 31, 2017 | $29.44M | – |
| Q4 FY2016 | Dec 31, 2016 | $35.52M | – |
| Q3 FY2016 | Sep 30, 2016 | $30.10M | – |
See a number that looks wrong?